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Abstract
Background: The World Health Organization initiative to eliminate mother-to-child transmission of syphilis aims for $90%
of pregnant women to be tested for syphilis and $90% to receive treatment by 2015. We calculated global and regional
estimates of syphilis in pregnancy and associated adverse outcomes for 2008, as well as antenatal care (ANC) coverage for
women with syphilis.
Methods and Findings: Estimates were based upon a health service delivery model. National syphilis seropositivity data
from 97 of 193 countries and ANC coverage from 147 countries were obtained from World Health Organization databases.
Proportions of adverse outcomes and effectiveness of screening and treatment were from published literature. Regional
estimates of ANC syphilis testing and treatment were examined through sensitivity analysis. In 2008, approximately 1.36
million (range: 1.16 to 1.56 million) pregnant women globally were estimated to have probable active syphilis; of these, 80%
had attended ANC. Globally, 520,905 (best case: 425,847; worst case: 615,963) adverse outcomes were estimated to be
caused by maternal syphilis, including approximately 212,327 (174,938; 249,716) stillbirths (.28 wk) or early fetal deaths (22
to 28 wk), 91,764 (76,141; 107,397) neonatal deaths, 65,267 (56,929; 73,605) preterm or low birth weight infants, and
151,547 (117,848; 185,245) infected newborns. Approximately 66% of adverse outcomes occurred in ANC attendees who
were not tested or were not treated for syphilis. In 2008, based on the middle case scenario, clinical services likely averted
26% of all adverse outcomes. Limitations include missing syphilis seropositivity data for many countries in Europe, the
Mediterranean, and North America, and use of estimates for the proportion of syphilis that was ‘‘probable active,’’ and for
testing and treatment coverage.
Conclusions: Syphilis continues to affect large numbers of pregnant women, causing substantial perinatal morbidity and
mortality that could be prevented by early testing and treatment. In this analysis, most adverse outcomes occurred among
women who attended ANC but were not tested or treated for syphilis, highlighting the need to improve the quality of ANC
as well as ANC coverage. In addition, improved ANC data on syphilis testing coverage, positivity, and treatment are needed.
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Introduction
Syphilis is a severe bacterial disease that in pregnancy may
manifest as stillbirth, early fetal death, low birth weight, preterm
delivery, neonatal death, or infection or disease in the newborn.
Both archaeological and literary evidence suggest that mother-to-
child transmission (MTCT) of syphilis, commonly referred to as
‘‘congenital syphilis,’’ is an ancient scourge [1,2]. In modern times
the effectiveness of syphilis testing and treatment in preventing
MTCT of syphilis is well-recognized [3]. Diagnosis and prevention
of MTCT of syphilis is feasible, inexpensive, and cost-effective in
nearly every situation evaluated [4]. Yet, despite the tools being
available for over 60 y, MTCT of syphilis persists as a public
health problem.
It is unknown exactly what proportion of pregnant women
globally receives adequate testing and treatment for syphilis. The
World Health Organization (WHO) has begun to monitor syphilis
testing and treatment coverage through the HIV Universal Access
reporting system, but quality data are not yet available from all
countries. In 2011, 63 of 149 low- and middle-income countries
reported on coverage of syphilis testing within antenatal care
(ANC), with a median of 68% of women in the reporting countries
being tested for syphilis at first ANC visit [5]. However, this
coverage estimate may be an overestimate of syphilis testing
coverage in low- and middle-income countries, as those countries
without a functional syphilis screening program are unlikely to
have a functional reporting system. A recent multi-country study
to assess introduction of rapid point-of-care tests found that ANC
syphilis testing at baseline was nonexistent in the Amazonas region
of Brazil, 1.7% in Kampala Hospital and rural ANC centers in
Uganda, 17.8% in the district hospital and 51 health facilities in
Geita District, Tanzania, 51% in a maternity hospital in Lima and
ANC centers in Callao, Peru, and 79.9% in Lusaka Hospital and
rural ANC centers in Mongu District, Zambia [6]. Other
individual country reports have also documented a low coverage
of testing and treatment of syphilis in pregnant women. For
example, a study in southern China found that 57% of pregnant
women were tested for syphilis from 2004 to 2008 [7]. Another
study in two provinces in South Africa found that although 71% of
pregnant women were tested for syphilis at first ANC visit, only
74% of women who tested positive for syphilis had treatment
documented, and only 36% of seropositive women with
documented treatment received the recommended three doses of
intramuscular penicillin [8].
In 2007, WHO launched its Initiative for the Global
Elimination of Congenital Syphilis, with the goal that by 2015 at
least 90% of pregnant women are tested for syphilis and at least
90% of seropositive pregnant women receive adequate treatment
[4]. The elimination initiative was designed around improving
four public health ‘‘pillars’’: political advocacy and community
engagement; adequate coverage and quality of ANC; access to and
quality of syphilis testing in ANC; and routine surveillance,
monitoring, and evaluation. The regions of the Americas and the
Asia Pacific have also launched elimination initiatives, in both
cases initiatives integrated with elimination of MTCT of HIV
[9,10].
In order to assess progress in elimination of MTCT of syphilis
and to guide policy and advocacy efforts, global data on the
burden of syphilis in pregnancy and associated adverse outcomes
are needed. Unfortunately, MTCT of syphilis cannot be easily
measured globally because definitive diagnosis is difficult, even in
developed countries with robust laboratory infrastructure. Thus,
estimating the burden of disease must rely on modeled data. In
2007 WHO reported global estimates for congenital syphilis
burden based on a review of published data from 1997 through
2003. This work estimated that annually there were 2,036,753
syphilis infections among pregnant women, of which 65%
(1,323,889; range: 728,547 to 1,527,565) resulted in adverse
pregnancy outcomes [11]. The 1997–2003 estimates were based
upon 45 published studies representing 31 countries. All included
studies had a sample size of at least 100 women and determined
syphilis seropositivity using both treponemal and non-treponemal
tests. The 1997–2003 estimates excluded studies from the United
States, Canada, and most of Europe because syphilis is rare in
these countries and they would not contribute meaningful
numbers of congenital syphilis. The 1997–2003 estimates also
did not take existing treatment services into account and did not
remove background mortality and morbidity (i.e., expected
adverse outcomes that would occur in uninfected women).
In order to support the global initiative for elimination of
congenital syphilis, WHO has developed 2008 global estimates of
maternal syphilis and associated adverse pregnancy outcomes. The
2008 numbers are intended not only to update the earlier 1997–
2003 estimates, but also to use a stronger methodology to take into
account existing treatment services, remove background mortality,
and incorporate data from a greater number of countries. These
updated estimates can be used to guide global and regional policy,
program, and advocacy efforts to strengthen maternal and child
health services and to monitor progress to eliminate MTCT of
syphilis.
Methods
The objective of this analysis was to estimate for 2008 the global
and regional number of pregnant women infected with probable
active syphilis, as well as the number of associated adverse
outcomes of syphilis in pregnancy. This analysis is based upon a
health service delivery model that involved four estimation steps
(Figure 1): calculation of the number of pregnant women with
probable active syphilis in each country, calculation of the number
of pregnant women with probable active syphilis in each region,
calculation of the number of adverse pregnancy outcomes
associated with syphilis in each region, and calculation of the
global number of adverse pregnancy outcomes related to syphilis.
Wherever possible, this analysis was done using data provided
routinely by countries to United Nations organizations (country-
specific data points are available in Dataset S1). Countries were
allocated to one of six regions based on WHO regional
classifications [12]. For this analysis we defined ‘‘probable active
syphilis infection’’ as seropositivity on both treponemal and non-
treponemal tests, because women without confirmed test results
may have had false positive tests or old or untreated disease that
would be unlikely to pose a risk of syphilis transmission to the fetus.
We defined ‘‘stillbirth’’ as death of a fetus of at least 28 wk
gestation or at least 1,000 g weight, and ‘‘early fetal death’’ as fetal
death occurring from 22 to 28 wk gestation (i.e., second and early
third trimester); we did not include first trimester losses (miscar-
riages) [13].
Step A: Estimate the Number of Pregnant Women with
Probable Active Syphilis in Each Country
For Step A1, data on syphilis seropositivity among ANC
attendees for each country were those data reported through the
WHO HIV Universal Access reporting system for 2008 (data
available at the WHO Global Health Observatory Data Repos-
itory: http://apps.who.int/gho/data/?theme =main). If 2008
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data were not available, we used data reported for 2009 (Figure 2).
In 2008 and 2009, data were reported for 97 of 193 countries
(50.3%). A regional median was used for countries that did not
report data in 2008 or 2009. Countries could report either ANC
sentinel survey results or routinely conducted antenatal program
data to the HIV Universal Access reporting system. In this
reporting system, type of syphilis test used is not reported; thus, it
was not possible to distinguish whether reported seropositivity was
based upon treponemal, non-treponemal, or combined test results.
The estimated number of pregnant women in Step A2 was
calculated for each country as the sum of the number of live births
per United Nations Population Division estimates for 2008,
stillbirths (after 28 wk gestation) per 2008 published estimates,
and early fetal deaths (22–28 wk gestation) [14]. Estimates of early
fetal deaths are not available for many countries; thus, we
estimated these to be approximately 20% of stillbirths based on the
early to late fetal death relationship in a limited number of studies
mainly in high-income countries [15,16]. Estimations of fetal
deaths did not include first trimester losses (miscarriages).
Step A3 included an estimation of the proportion of seropositive
pregnant women with probable active syphilis infection. A value of
65% was used as a correction factor to estimate the proportion of
seropositive women with both treponemal and non-treponemal
syphilis test positivity for the data reported through the HIV
Universal Access reporting system. The correction factor was
based on data from a literature review of 45 studies on syphilis in
pregnancy from 2004 to 2008 [17]. Of these, three studies
reported results of treponemal and non-treponemal tests for all
pregnant women [18–20]. Among all women with either syphilis
test positive, the proportion of women with both the treponemal
test and the non-treponemal test positive was found to be 63.9% in
Mozambique, 61.7% in Bolivia, and 68.0% in Tanzania.
Step A4 involved estimating for each country the proportion of
pregnant women with and without at least one ANC visit. We used
the most recent data for a country available in the WHO Global
Health Observatory from 2000 to 2010; data were available for
147 countries [21]. A regional median was used for countries for
which data were not available. The four values in Step A were
multiplied to obtain the estimated number of pregnant women
infected with probable active syphilis attending and not attending
ANC in each country.
An approximate uncertainty range for the global number of
pregnant women with probable active syphilis was calculated using
the delta method and a 10% relative error at the national level for
three input variables: syphilis seropositivity, number of pregnan-
cies, and the correction factor for the estimated proportion of
women with syphilis with probable active disease.
Step B: Estimate the Number of Pregnant Women
Infected with Probable Active Syphilis in Each Region
Step B involved summing the country values to provide regional
estimates of the number of pregnant women with probable active
syphilis not attending ANC (B1), as well as the number attending
ANC (B2).
Step C: Estimate the Number of Adverse Pregnancy
Outcomes Associated with Syphilis in Each Region
The objective of Step C was to estimate for each region the total
number of adverse pregnancy outcomes related to maternal
syphilis. We calculated the number of specific adverse pregnancy
Figure 1. Flowchart of model to estimate number of adverse outcomes associated with syphilis in pregnancy. #, number.
doi:10.1371/journal.pmed.1001396.g001
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outcomes in five categories: any adverse outcome, stillbirth or
early fetal death, neonatal death, prematurity or low birth weight,
and an infected newborn. Because of the limited availability of
data on the proportion of pregnant women tested in ANC and, of
those found to be positive, the proportion treated adequately, we
devised a simple sensitivity analysis that considered three testing
and treatment coverage scenarios defined in consultation with
WHO regional advisors: worst, middle, and best case (Table 1). In
addition, we considered the scenario proposed as a target for 2015
in the WHO Initiative for the Global Elimination of Congenital
Syphilis, in which at least 90% of pregnant women are tested for
syphilis at first antenatal visit, and at least 90% of seropositive
pregnant women are adequately treated (i.e., testing and treatment
coverage T=81% for all regions, except Europe, which was
assumed to maintain T=90%).
In Step C1, the total number of adverse outcomes in pregnant
women with probable active syphilis who did not attend ANC was
calculated as the product of the regional number of infected
pregnant women not attending ANC and the proportion P of
those women expected to have a syphilis-related adverse outcome
without treatment. P for each adverse outcome category was
obtained from a meta-analysis of published clinical literature
assessing adverse pregnancy outcomes among women
with probable active syphilis without adequate treatment:
Pany adverse outcome = 0.52, Pstillbirth/early fetal death = 0.21,
Pneonatal death = 0.09, Pprematurity/low birth weight = 0.06, and
Pinfected newborn = 0.16 [22].
We also estimated the number of adverse outcomes in pregnant
women with probable active syphilis who attended ANC (Step C2
and Step C3). Not all women who attend ANC are tested for
syphilis and adequately treated if seropositive. Therefore, we
estimated adverse outcomes for women who were both tested
and treated (T) (Table 1), as well as for those who were not (12T). In
women who are not both tested and treated, the number of adverse
outcomes is the number not tested and treated multiplied by the
proportion expected to have an adverse outcome (P). Even
among women who are both tested and treated, a small number of
adverse events can be expected, particularly if syphilis cases are
identified late in pregnancy. A systematic review by Blencowe et al.
found that the effectiveness E of screening and treatment with
penicillin in reducing adverse outcomes was as follows: Eneonatal
death =0.80, Eprematurity/low birth weight = 0.64, and Einfected new-
born=0.97 [23]. For this analysis, Estillbirth/early fetal death = 0.82 was
based on the estimate of effectiveness for stillbirth alone, and Eany
adverse outcome=0.84 was based on the weighted mean of Eneonatal death,
Eprematurity/low birth weight, Einfected newborn, and Estillbirth/early fetal death,
using as weights the proportion of women with the corresponding
adverse outcome.
Step D: Estimate the Global Number of Adverse
Pregnancy Outcomes Related to Syphilis
Step D summed the regional estimates for each adverse
outcome to produce a global estimate of the number of adverse
pregnancy outcomes related to syphilis.
Finally, we calculated the number of adverse pregnancy
outcomes averted by current services by subtracting the number
of adverse outcomes in the middle case testing-and-treatment-
coverage scenario from a baseline number of adverse outcomes
estimated in the absence of any services.
Figure 2. Syphilis seropositivity among antenatal care attendees reported by countries through the WHO HIV Universal Access
reporting system in 2008 or 2009, and regional median for non-reporting countries.
doi:10.1371/journal.pmed.1001396.g002
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Results
We estimated that in 2008 there were 1,360,485 (range
1,160,195–1,560,776) pregnant women with probable active
syphilis infections, and of these women, 1,085,637 (79.8%)
attended ANC. The estimated number of infected pregnant
women by region was 535,203 in Africa (39.3%), 106,500 in the
Americas (7.8%), 603,293 in Asia (44.3%), 21,602 in Europe
(1.6%), 40,062 in the Mediterranean (3.0%), and 53,825 (4.0%) in
the Pacific. Without any screening or treatment services, these
pregnant women with probable active syphilis would have had
707,452 adverse pregnancy outcomes, including 285,702 stillbirths
or early fetal deaths, 122,444 neonatal deaths, 81,629 premature
or low birth weight infants, and 217,678 infected newborns. Thus,
in the absence of any antenatal syphilis screening and treatment,
an estimated 408,146 fetal or perinatal deaths and 299,307 infants
at risk for early death would have resulted from maternal syphilis
infection.
Figure 3 shows the estimated number of adverse outcomes in
2008 associated with syphilis globally and by region for the worst,
middle, and best case scenarios of testing and treatment of women
who are seropositive. Considering the middle case scenario, we
estimated that globally there were 520,905 (best: 425,847; worst:
615,963) adverse outcomes associated with syphilis in pregnancy,
which included 212,327 (best: 174,938; worst: 249,716) stillbirths
or early fetal deaths, 91,764 (best: 76,141; worst: 107,397)
neonatal deaths, 65,267 (best: 56,929; worst: 73,605) preterm or
low birth weight infants, and 151,547 (best: 117,848; worst
185,245) infected newborns. In summary, globally in 2008 in a
middle case scenario, untreated maternal syphilis resulted in
approximately 304,091 fetal or perinatal deaths and 216,814
syphilis-infected infants at risk for early death. Examination of any
adverse outcome by region showed that the majority of adverse
outcomes (87%) were in Africa and Asia. Of note, 66% of all
adverse outcomes occurred in women who had attended ANC.
In 2008, using the middle case scenario for antenatal screening
and treatment, approximately 186,548 (26%) of all adverse
outcomes of syphilis in pregnancy were averted. Specifically, the
averted outcomes were 73,375 stillbirths or early fetal deaths,
30,679 neonatal deaths, 16,362 preterm or low birth weight
infants, and 66,131 infected newborns (Table 2). By region, the
number of all adverse outcomes averted in 2008 in the middle case
scenario was estimated as 54,676 in Africa, 26,318 in the
Americas, 82,949 in Asia, 6,447 in Europe, 3,398 in the
Mediterranean, and 12,758 in the Pacific. If the elimination
initiative targets for 2015 of at least 90% testing and 90%
treatment had been reached in 2008, then 385,815 (55%) of all
adverse outcomes could have been averted: 151,753 stillbirths or
early fetal deaths, 63,451 neonatal deaths, 33,840 preterm or low
birth weight infants, and 136,771 infected newborns.
Discussion
Globally, nearly 1.4 million pregnant women in 2008 had
probable active syphilis infection and were at risk of transmitting
the disease perinatally to their unborn children. This is lower than
previously reported 1997–2003 WHO estimates of approximately
2 million pregnant women annually with untreated syphilis
infection, and suggests some progress may have been made over
the past decade in syphilis prevention and control. However, the
extent of progress is difficult to determine, as the estimates used
differing methodological approaches. In comparison to the 1997–
2003 estimates, the 2008 estimates were intended to take into
account existing treatment services, remove background mortality
and morbidity unrelated to syphilis, and better account for the
anticipated increasing availability of testing and treatment over
time. In addition, because of the paucity of published cross-
sectional survey data since 2003 on syphilis in pregnancy, the 2008
estimates were based on data reported to WHO routinely by
countries through the HIV Universal Access reporting system
rather than on data from a literature review.
Despite differences in methodology, both the 1997–2003 and
the 2008 estimates indicate that syphilis in pregnancy continues to
be an important cause of mortality and morbidity in pregnancy.
This is unsettling given the fact that universal syphilis screening in
ANC and prompt treatment of women testing positive are basic
interventions that have been proven to be cost-effective even in
low prevalence settings. Additionally, rapid point-of-care syphilis
tests allowing testing and treatment in almost any clinical setting
were not widely available in 2003, but certainly should have been
by 2008. These 2008 estimates support that countries in every
region of the world should scale up screening and treatment for
syphilis in pregnancy, and that doing so could substantially reduce
preventable perinatal death and disability.
Our estimates suggest that over 520,000 adverse pregnancy
outcomes due to syphilis occurred in 2008, of which approxi-
mately 215,000 were stillbirths or early fetal deaths, 90,000 were
neonatal deaths, 65,000 were premature or low birth weight
infants, and another 150,000 were infected newborns. Our
estimates do not include additional deaths that would be expected
Table 1. Estimated proportion of antenatal care attendees tested and treated in different scenarios for 2008, and proposed
Initiative for the Global Elimination of Congenital Syphilis target for 2015.
Region Worst Case 2008 Middle Case 2008 Best Case 2008
Proposed Syphilis
Elimination Target 2015
Africa 10% 30% 50% 81%
Americas 40% 60% 80% 81%
Asia 20% 40% 60% 81%
Europe 50% 70% 90% 90%
Mediterranean 10% 30% 50% 81%
Pacific 40% 60% 80% 81%
If a country tested 80% of all pregnant women, and 80% of those found to be seropositive received appropriate treatment, then T= 0.860.8 = 64%. The proposed 2015
target for the Initiative for the Global Elimination of Congenital Syphilis is that at least 90% of pregnant women are tested for syphilis and at least 90% of seropositive
pregnant women receive treatment (T= 0.960.9 = 81%). This would apply for all regions except Europe, on the assumption that Europe would be unlikely to provide a
lower standard of care than the 2008 best case scenario of T= 90%.
doi:10.1371/journal.pmed.1001396.t001
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to occur after the first month of life due to prematurity, low birth
weight, or congenital infections, estimated in one study to result in
approximately 10% mortality by 1 y (i.e., approximately 21,500
additional infant deaths) [24].
Approximately one-fifth (20%) of all pregnant women with
syphilis did not attend ANC. Thus, efforts to ensure universal
access to early ANC are fundamental in eliminating congenital
syphilis, as well as other causes of preventable infant mortality. But
importantly, our data suggest that two-thirds of the adverse
outcomes due to syphilis occurred in women who had attended
ANC at least once, but either were not screened or, if they were
screened and tested positive, did not receive appropriate treatment
with intramuscular benzathine penicillin. The vast majority of
outcomes that occurred in 2008 could have been prevented had
the women received quality early ANC that included syphilis
testing and access to effective therapies, as recommended by
WHO. Syphilis testing and treatment are relatively inexpensive
compared with other interventions, with tests typically costing less
than US$1, and treatment slightly less than that. To reduce cases
of congenital syphilis, it will be important to incorporate syphilis
testing and treatment into routine procurement and distribution
systems to ensure that pregnant women receive an essential
minimal package of ANC interventions.
Existing health care services were able to avert one out of every
four expected adverse outcomes in 2008. However, if the proposed
testing and treatment targets for 2015 outlined in the Initiative for
the Global Elimination of Congenital Syphilis had been reached in
2008, over half of all expected adverse outcomes could have been
averted. Further research is needed to define how many cases and
what level of service delivery is needed to attain the ultimate goal
of ‘‘elimination of congenital syphilis as a public health problem.’’
However, given that screening and treatment for preventing
MTCT of syphilis is not 100% effective, primary prevention of
syphilis in pregnant women is also an important strategy that
needs to be addressed to truly eliminate congenital syphilis.
While substantial progress has been made in the utilization of
ANC (in 2009 WHO estimated that approximately 81% of all
pregnant women had attended at least one ANC visit) [25],
congenital syphilis still occurred for a variety of reasons: many of
these visits were too late to avert an adverse outcome, clinics may
not have offered testing, testing may not have been affordable,
women may not have followed up or received their test results,
treatment may not have been available, or treated women may
have been reinfected by untreated sexual partners [26].
Our estimates are subject to some limitations. First, there are no
global data on estimated numbers of early fetal deaths; national
estimates of early fetal deaths had to be crudely extrapolated from
estimated numbers of stillbirths using a correction factor based
mainly on data from high-income countries. Improved data on
early fetal death, in particular in low- and middle-income
Figure 3. Estimated number of adverse outcomes associated with syphilis in pregnancy in a worst, middle, and best case scenarios
of testing and treatment in 2008. LBW, low birth weight.
doi:10.1371/journal.pmed.1001396.g003
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countries, is necessary to understand the full extent of the impact
of this limitation.
In addition, these estimates rely on data reported through the
HIV Universal Access reporting system and do not include
separate published studies of syphilis seropositivity, as was
previously done for the 1997–2003 estimates. The advantage of
HIV Universal Access data is that they are reported by most
developing countries on a routine basis, involve a larger sample
size than most published studies, and are less subject to a
publication bias. However, several countries did not report
through the HIV Universal Access system, including some high-
income countries in North America, Europe, and the Mediterra-
nean with low syphilis seropositivity, as well as some particularly
low resource countries without organized screening programs and
with high syphilis seropositivity. It is unclear how this underre-
porting would affect the overall estimates.
Although countries are asked to report nationally representative
data, it is possible that these data are over-representative of urban
populations with greater access to syphilis prevention and
treatment services than rural populations. If syphilis seropositivity
is higher in rural settings (and programs are less effective), our
calculations may underestimate the true burden of syphilis-
associated adverse outcomes.
In addition, HIV Universal Access data do not include
information on testing methodologies, test titer, stage of disease,
or treatment history, and therefore it is unclear whether or not a
country’s data includes women with latent or previously treated
disease. This analysis applied a correction factor for ‘‘probable
active’’ disease to the entire dataset to account for this; however,
adjustment may not have been necessary in all cases and may have
led to underestimation of the true burden of active disease.
Because of a lack of representative data on current testing and
treatment coverage, these estimates relied on expert opinion of
current testing and treatment coverage, and the experts may have
miscalculated. In order to explore the validity of these estimates,
we present a basic sensitivity analysis of testing and treatment
coverage to account for the uncertainty related to this approxi-
mation. Although WHO is working to improve collection of data
on syphilis testing and treatment through the HIV Universal
Access reporting system, these testing and treatment data are not
yet felt to be accurate and representative at a global level (the
highest performing countries are more likely to report service
delivery indicators). Thus, more work with countries to strengthen
surveillance and monitoring systems is needed.
Finally, these estimates do not account for the timing of
treatment of syphilis in pregnancy. Although syphilis transmission
has been documented to occur very early in pregnancy, existing
data suggest that catastrophic outcomes due to syphilis require
development of the fetal immune system (i.e., after 18–20 wk
gestation) [27]. It is also recognized that the effectiveness of
screening and treatment is lower in the third trimester than in the
first and second trimesters [28].
The limitations of these estimates highlight the urgent need for
improved data through stronger national surveillance and
monitoring systems. All countries should know at least the three
core indicators related to MTCT of syphilis in their population:
what proportion of ANC attendees are tested for syphilis, what
proportion are seropositive, and what proportion of syphilis
seropositive ANC attendees are adequately treated [29]. WHO
hopes to work with countries to improve capacity to monitor and
report on these three core indicators through the WHO HIV
Universal Access reporting system. Better national data are also
needed on how early pregnant women seek care and how many
women have early fetal deaths, as well as how estimates of adverse
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outcomes such as congenital syphilis and stillbirth attributable to
syphilis compare to actual reported cases of congenital syphilis and
stillbirth attributable to syphilis.
In summary, this analysis indicates that syphilis continues to be
an important cause of adverse outcomes of pregnancy, including
substantial numbers of perinatal deaths and disabilities. Given that
an increasing proportion of the infant mortality that Millennium
Development Goal 4 aims to address by 2015 occurs during the
first month of life, investing in elimination of MTCT of syphilis is a
low-hanging fruit for reducing neonatal mortality, as well as
stillbirths. Primary prevention of syphilis in people of reproductive
age is an important first step towards reducing these deaths. Better
data are needed to raise local awareness of the burden of syphilis
in pregnancy, an old scourge that is often overlooked in modern
day public health programs. Countries also need to ensure that
quality-assured syphilis testing is available in all ANC settings, now
possible even in remote care settings with the introduction of rapid
point-of-care diagnostics. In addition, efforts are needed to ensure
universal access to early ANC, as well as improved quality of
ANC, so that all pregnant women receive an essential package of
services that includes routine and early access to point-of-care
testing and adequate treatment for syphilis if seropositive. MTCT
of syphilis can only be eliminated if decision-makers at all levels
prioritize the provision and quality of this basic ANC service.
Elimination of MTCT of syphilis directly supports attainment of
Millennium Development Goals 4, 5, and 6 through reduction in
infant mortality, improved maternal health, and primary preven-
tion of HIV [30]. With just a short amount of time left to achieve
the Millennium Development Goals, the United Nations Secre-
tary-General launched the Global Strategy for Women’s and
Children’s Health, which calls for improved coordination around
maternal and newborn health issues [31]. Bringing ministries of
health and partners together to provide universal coverage of
antenatal syphilis screening and to ensure treatment of all
pregnant women infected with syphilis is a specific example of
an activity that would greatly support the Global Strategy for
Women’s and Children’s Health.
Supporting Information
Dataset S1 Country-level data and assumptions used
for 2008 estimates of syphilis in pregnancy and associ-
ated adverse outcomes.
(XLSX)
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Editors’ Summary
Background. Syphilis—a sexually transmitted bacterial
infection caused by Treponema pallidum—can pass from a
mother who is infected to her unborn child. Screening
pregnant women for syphilis during routine antenatal care
by looking for a reaction to T. pallidum in the blood
(seropositivity) and then treating any detected infections
with penicillin injections has been feasible for many years,
even in low-resource settings. However, because coverage of
testing and treatment of syphilis remains low in many
countries, mother-to-child transmission of syphilis—‘‘con-
genital syphilis’’—is still a global public health problem. In
2007, the World Health Organization (WHO) estimated that
there were 2 million syphilis infections among pregnant
women annually, 65% of which resulted in adverse
pregnancy outcomes: the baby’s death during early or late
pregnancy (fetal death and stillbirth, respectively) or soon
after birth (neonatal death), or the birth of an infected baby.
Babies born with syphilis often have a low birth weight and
develop problems such as blindness, deafness, and seizures
if not treated.
Why Was This Study Done? In 2007, WHO launched an
initiative to eliminate congenital syphilis that set targets of at
least 90% of pregnant women being tested for syphilis and
at least 90% of seropositive pregnant women receiving
adequate treatment by 2015. To assess the initiative’s
progress and to guide policy and advocacy efforts, accurate
global data on the burden of syphilis in pregnancy and on
associated adverse outcomes are needed. Unfortunately,
even in developed countries with good laboratory facilities,
definitive diagnosis of congenital syphilis is difficult. Esti-
mates of the global burden can be obtained, however, using
mathematical models. In this study, the researchers generate
global and regional estimates of the burden of syphilis in
pregnancy and associated adverse outcomes for 2008 using
a health services delivery model.
What Did the Researchers Do and Find? The researchers
developed a mathematical model to estimate the number of
syphilis-infected pregnant women in each country and in
each region, and to estimate the regional and global
numbers of adverse pregnancy outcomes associated with
syphilis. They used national syphilis seropositivity data and
information on antenatal care coverage from WHO and
estimates of the effectiveness of screening and treatment
from published literature. Using these data and their model,
the researchers estimated that, in 2008, 1.4 million pregnant
women, 80% of whom had attended antenatal care services,
had an active syphilis infection. Assuming a scenario in which
the percentage of pregnant women tested for syphilis and
adequately treated ranged from 30% for Africa and the
Mediterranean region to 70% for Europe (a scenario defined
in consultation with WHO advisors), the researchers estimat-
ed that maternal syphilis caused 520,000 adverse outcomes
in 2008, including 215,000 stillbirths or fetal deaths, 90,000
neonatal deaths, 65,000 preterm or low birth weight infants,
and 150,000 infants with congenital disease. About 66% of
these adverse effects occurred in women who had attended
antenatal care but were either not tested or not treated for
syphilis. Finally, the researchers estimated that in 2008,
clinical services averted 26% of all adverse outcomes.
What Do These Findings Mean? These findings, which
update and extend previous estimates of the global burden
of congenital syphilis, indicate that syphilis continues to
affect a large number of pregnant women and their
offspring. The current findings, which cannot be directly
compared to previous estimates because of the different
methodologies used, are likely to be affected by the accuracy
of the data fed into the researchers’ model. In particular, the
data on the percentage of the population infected with
syphilis in individual countries used in this study came from
the HIV Universal Access reporting system and may not be
nationally representative. Nevertheless, these findings sug-
gest that syphilis continues to be an important cause of
adverse outcomes of pregnancy, partly because pregnant
women often do not receive syphilis screening and prompt
treatment during routine antenatal care. The researchers
recommend, therefore, that all countries should ensure that
all pregnant women receive an essential package of high-
quality antenatal care services that includes routine and easy
access to syphilis testing and treatment. Congenital syphilis,
they conclude, can only be eliminated if decision-makers at
all levels prioritize the provision, quality, and monitoring of
this basic antenatal care service, which has the potential to
reduce infant mortality and improve maternal health.
Additional Information. Please access these websites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001396.
N The World Health Organization provides information on
sexually transmitted diseases, including details of its
strategy for the global elimination of congenital syphilis,
the investment case for the elimination of mother-to-child
transmission of syphilis, and regional updates on progress
towards elimination (some information is available in
several languages)
N The Pan American Health Organization provides informa-
tion on efforts to eliminate congenital syphilis in Latin
America (in English and Spanish), and the Asia-Pacific
Prevention of Parent-to-Child Transmission Task Force
provides information on efforts to eliminate congenital
syphilis in Asia Pacific
N The US Centers for Disease Control and Prevention has a
fact sheet on syphilis (in English and Spanish)
N The UK National Health Service Choices website also has a
page on syphilis
N MedlinePlus provides information on congenital syphilis
and links to additional syphilis resources (in English and
Spanish)
N The London School of Hygiene and Tropical Medicine
provides a toolkit for the introduction of rapid syphilis tests
N ‘‘Haiti: Congenital Syphilis on the Way Out’’ is a YouTube
video describing the introduction of rapid diagnostic tests
for syphilis in remote parts of Haiti
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